Evidence-based insights on healthcare investing, physician advisory work, and startup due diligence — for physician investors and the startups they fund.
Medicare's 2026 payment reset sharply changes the economics of skin-substitute products and wound-care companies. Physic…
The 2026 CMS requirements make hospital pricing data more structured and more useful, but they do not make every price c…
The 2025 court decision removed FDA's laboratory-developed-test phaseout rule, but it did not remove validation, state a…
For a connected medical-device startup, cybersecurity is a product-lifecycle capability rather than a premarket attachme…
Medicare now pays for a narrow digital mental health treatment-device pathway, not for mental health apps in general. Th…
The 2026 Part 2 transition changed how substance use disorder records can move for treatment, payment, and health care o…
CMS prior authorization reform creates a near-term market for payer, provider, and workflow technology, but a FHIR endpo…
TEFCA can widen a digital health startup's path to nationwide clinical data, but participation does not guarantee comple…
CMS TEAM creates a defined 2026 market for tools that help participating hospitals manage surgical episodes, but mandato…
ONC HTI-1 creates a transparency and risk-management layer for predictive decision support in certified health IT, but i…
The FTC Health Breach Notification Rule can apply to many consumer health apps outside HIPAA, including unauthorized dat…
An FDA-authorized predetermined change control plan can reduce regulatory friction for specified AI medical device updat…
The new CMS-FDA RAPID pathway could shorten the distance between FDA authorization and Medicare coverage for eligible Br…
Healthcare diligence requires an integrated review of clinical evidence, regulation, reimbursement, workflow, compliance…